These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 32767673)

  • 1. Use of Real-World Data to Emulate a Clinical Trial and Support Regulatory Decision Making: Assessing the Impact of Temporality, Comparator Choice, and Method of Adjustment.
    Abrahami D; Pradhan R; Yin H; Honig P; Baumfeld Andre E; Azoulay L
    Clin Pharmacol Ther; 2021 Feb; 109(2):452-461. PubMed ID: 32767673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden.
    Svanström H; Ueda P; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Pasternak B
    Lancet Diabetes Endocrinol; 2019 Feb; 7(2):106-114. PubMed ID: 30527909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies.
    Azoulay L; Suissa S
    Diabetes Care; 2017 May; 40(5):706-714. PubMed ID: 28428321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining Clinically Relevant Target Populations Using Real-World Data to Guide the Design of Representative Antidiabetic Drug Trials.
    Pradhan R; Abrahami D; Yin H; Yu OHY; Sahasrabudhe V; Baumfeld Andre E; Azoulay L
    Clin Pharmacol Ther; 2021 May; 109(5):1219-1223. PubMed ID: 33615445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Effects of Liraglutide.
    Mikhail N
    Curr Hypertens Rev; 2019; 15(1):64-69. PubMed ID: 29737256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial.
    Nauck MA; Tornøe K; Rasmussen S; Treppendahl MB; Marso SP;
    Diab Vasc Dis Res; 2018 Sep; 15(5):465-468. PubMed ID: 29947247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Risk of TB in Patients With Type 2 Diabetes Initiating Metformin vs Sulfonylurea Treatment.
    Pan SW; Yen YF; Kou YR; Chuang PH; Su VY; Feng JY; Chan YJ; Su WJ
    Chest; 2018 Jun; 153(6):1347-1357. PubMed ID: 29253553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality risk among sulfonylureas: a systematic review and network meta-analysis.
    Simpson SH; Lee J; Choi S; Vandermeer B; Abdelmoneim AS; Featherstone TR
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):43-51. PubMed ID: 25466239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Possibilities of influencing cardiovascular risk in type 2 diabetes mellitus by antidiabetic treatment Lowering of cardiovascular risk in treatment with liraglutide - Results of the LEADER].
    Olšovský J
    Vnitr Lek; 2016; 62(7-8):613-5. PubMed ID: 27627086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study.
    Douros A; Dell'Aniello S; Yu OHY; Filion KB; Azoulay L; Suissa S
    BMJ; 2018 Jul; 362():k2693. PubMed ID: 30021781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Jensen TM; Saha K; Steinberg WM
    Diabetes Care; 2015 Jun; 38(6):1058-66. PubMed ID: 25504028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study.
    Patorno E; Goldfine AB; Schneeweiss S; Everett BM; Glynn RJ; Liu J; Kim SC
    BMJ; 2018 Feb; 360():k119. PubMed ID: 29437648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial.
    Athyros VG; Katsiki N; Tentolouris N
    Curr Vasc Pharmacol; 2016; 14(5):469-473. PubMed ID: 27633290
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes.
    Min JY; Griffin MR; Hung AM; Grijalva CG; Greevy RA; Liu X; Elasy T; Roumie CL
    J Gen Intern Med; 2016 Jun; 31(6):638-46. PubMed ID: 26921160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. After 10 Years of Clinical Trials with Liraglutide in Diabetes, What do we Know About its Effects on Clinical Cardiovascular Outcomes?
    Doggrell SA
    Rev Recent Clin Trials; 2015; 10(1):68-77. PubMed ID: 25881636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. London buses: A cardiovascular outcome trial equivalent?
    Grant PJ
    Diab Vasc Dis Res; 2016 Nov; 13(6):382-383. PubMed ID: 27543327
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.